This is a randomised, placebo-controlled, double-blinded, multi-centre, 2-part study to
assess the efficacy and safety of inhaled AZD1402. Part 1 will be performed in a lead-in
cohort for each dose level to evaluate the safety and pharmacokinetics (PK) in a population
with asthma controlled on medium dose inhaled corticosteroids (ICS)-long acting beta agonists
(LABA) before progressing to dosing in adults with asthma who are uncontrolled on medium dose
ICS-LABA in Part 2. The study will recruit participants receiving treatment with medium dose
ICS with LABA for Part 1 (separate inhalers or combination product) and medium dose ICS-LABA
as a combination product for Part 2 at Screening.
Part 2 will be initiated for each dose level following evaluation of safety and PK at the
relevant dose level in Part 1. The entire study period for each participant in both Parts 1
and 2, is approximately 3.5 months; a 2-week Screening Period, a 4 week Run-in Period, 4
weeks of Treatment Period, and 4 weeks of Follow-Up Period.